Quick Facts

• Addresses: The inability to achieve or sustain an erection (Erectile Dysfunction) in adult men.
• Manages: High blood pressure in the arteries of the lungs (Pulmonary Arterial Hypertension).

Sildenafil Adair is indicated for managing specific medical conditions in adults, focusing on circulatory and erectile function. The medication is used to address Erectile Dysfunction (ED), which involves difficulty achieving or maintaining an erection adequate for sexual performance. Through its intended action, Sildenafil Adair may help improve blood flow in the relevant area during periods of sexual stimulation.

Additionally, Sildenafil Adair is prescribed for the management of Pulmonary Arterial Hypertension (PAH), a condition characterized by high blood pressure in the blood vessels connecting the heart and lungs. For individuals diagnosed with PAH, the medication may help to improve exercise capacity and the overall ability to be physically active. Treatment with this medication should always be conducted under the direction of a qualified healthcare professional.

The eligibility for Sildenafil Adair is strictly defined by regulatory documents, distinguishing between approved, contraindicated, and restricted populations.

Eligibility Scope

Population Status	Regulatory Statement
Allowed	Adult Men for Erectile Dysfunction (ED) and Adults for Pulmonary Arterial Hypertension (PAH).
Not Recommended	Patients with severe hepatic impairment (for ED); chronic use in pediatric PAH due to safety concerns.
Contraindicated	Use with any organic nitrates or nitric oxide donors (including riociguat).
Contraindicated	Patients with a history of Non-Arteritic Anterior Ischaemic Optic Neuropathy (NAION) or certain hereditary retinal disorders.
Contraindicated	Recent stroke or myocardial infarction (within six months); resting hypotension (BP < 90/50 mmHg).

Age and Condition-Based Rules

• Age Limitations: The medicine is not indicated for children and adolescents for the ED use. Use in older adults (65 years and over) requires caution due to potential age-related organ changes.
• Organ Function: Use requires caution in patients with severe renal impairment (creatinine clearance < 30 mL/min) or hepatic impairment (e.g., cirrhosis), which can affect drug clearance.
• Restrictions: Caution is necessary for patients with conditions predisposing them to a prolonged erection, such as sickle cell anaemia, or specific anatomical penile deformities.

Interactions with other medicines and products

The interaction profile of Sildenafil Adair is strictly defined by regulatory documents based on two main categories: contraindicated combinations and pharmacokinetic interactions.

Classification	Official Restriction
Absolute Contraindications	The co-administration of Sildenafil is prohibited with Nitrates (in any form) and Riociguat.
Exposure Modification	Co-administration with strong CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) significantly increases Sildenafil plasma concentration and reduces its clearance.

---

Official Interaction Statements

The use of Sildenafil Adair is strictly contraindicated with organic nitrates and nitric oxide donors across all regulatory documentation due to the severe, documented risk of potentiating hypotensive effects. The combination with Riociguat, a guanylate cyclase stimulator, is similarly prohibited.

Pharmacokinetic interactions occur because Sildenafil is primarily cleared by the CYP3A4 enzyme. Substances that inhibit this enzyme, such as Ritonavir, lead to a marked increase in Sildenafil exposure, which establishes a formal dose restriction constraint.

A separate interaction exists with alpha-blockers that can result in symptomatic hypotension, particularly documented within four hours after Sildenafil administration. Official labeling notes that a high-fat meal slows the rate of absorption and decreases the maximum concentration of the medicine. Regulatory notes also identify that reduced clearance in patients with hepatic or severe renal impairment affects overall drug exposure.

How Sildenafil Adair Works at the Biological Level

Sildenafil Adair exerts its primary action as a selective competitive inhibitor of the enzyme phosphodiesterase type 5 (PDE5). This molecular interaction occurs primarily in the smooth muscle cells of the corpus cavernosum and vascular tissue.

The drug's action is predominantly coupled to the Nitric Oxide (NO) / cGMP signaling pathway. When local nerve stimulation triggers the release of NO, the subsequent generation of cGMP is enhanced. By inhibiting PDE5, Sildenafil Adair prevents the degradation of cGMP, causing its necessary accumulation within the smooth muscle cells.

This rise in cGMP concentration directly causes the relaxation of vascular smooth muscle cells (vasodilation) in the arteries supplying the corpus cavernosum. This localized change in muscle tone increases blood flow into the corpus cavernosum, modulating the system-level physiological response.

Sildenafil Adair is administered via oral and intravenous (IV) routes, with the chosen method and dosage strictly dependent on the approved indication. The oral forms include film-coated tablets and a reconstituted oral suspension. The IV injection is primarily reserved for patients with Pulmonary Arterial Hypertension (PAH) who are temporarily unable to take the oral preparation.

---

The general use pattern is divided between intermittent and continuous application:

Indication	Dosing Pattern	Maximum Frequency
Erectile Dysfunction (ED)	50 mg as needed; range: 25 mg to 100 mg	Once per day
Pulmonary Arterial Hypertension (PAH)	20 mg oral (TID), up to 80 mg oral (TID)	Three times per day (TID)

---

For the treatment of ED, the tablet is typically taken about one hour before activity, though the administration window ranges from 30 minutes to 4 hours. The medication may be taken with or without food; however, a high-fat meal can prolong the time to onset of action.

Certain populations may require dosage adjustments when treating ED. A reduced starting dose of 25 mg is considered for older adults (≥ 65 years) and for patients with severe hepatic or renal impairment. For the scheduled PAH regimen, if a dose is missed, patients are instructed to take the next dose at the regular scheduled time and are not to take a double dose to compensate. The oral suspension for PAH requires specific reconstitution and shaking instructions before use.

Research for Sildenafil Adair has focused on its two regulated uses: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). The evidence for both conditions is derived from controlled clinical trials and large-scale reviews, with research describing patterns related to both conditions.

The evidence base for ED is derived from a large number of short-term, randomized, placebo-controlled clinical trials. Researchers examined outcomes related to daily functioning by monitoring scores on specific erectile function questionnaires. Trials also explored the proportion of patients who reported a sexual intercourse attempt. Long-term effects are not fully established beyond the multi-year observation periods that track continued use. Data for certain groups, such as those with severe nerve or vascular damage, remain insufficient, as results apply only to the populations studied in the primary trials.

Research for PAH involved controlled studies that monitored physical performance measures such as the 6-minute walk distance (6MWD) and WHO Functional Class. Studies also tracked the time elapsed until a pre-defined clinical event was observed. Sildenafil was evaluated in men with diabetes mellitus and those who had undergone radical prostatectomy for ED.

For PAH, research was also evaluated in pediatric patients (children aged 1 to 17 years). One long-term extension study monitored outcomes and reported findings that included an association with increased mortality at the highest doses in the studied pediatric population. Because of this observation, certainty remains low regarding the optimal long-term management of children, leading to differing guidance from global regulatory bodies. A key limitation across the research base is that long-term effects are not fully established for continuous, multi-year use.

Common questions about Sildenafil Adair (FAQ)

Q: Can I take this medicine with alcohol?

A: Official regulatory documents contain a specific warning regarding alcohol consumption while using this medicine. This is due to the potential for interaction, which may lead to or worsen certain adverse reactions, such as effects on the central nervous system (CNS). This potential interaction is noted in the official product information.

Q: What should I do if I forget a dose?

A: Official dosing instructions generally advise taking the missed dose as soon as remembered, unless the next dose is due shortly, in which case the missed dose is typically skipped. This specific guidance is detailed in the patient information leaflet.

Q: Does this medication cause drowsiness or make you sleepy?

A: Studies and official information indicate that drowsiness, medically referred to as somnolence or sedation, has been reported as a common or very common adverse reaction during clinical trials and post-marketing surveillance. This potential effect is noted in the official product information.

Q: Is this medicine safe for children under 12 years old?

A: The official product information states that the safety and effectiveness of this drug in pediatric patients younger than 12 years of age have not been definitively established. Consequently, official regulatory documents state that use in this younger age group may be restricted or contraindicated.

Q: How should I store the tablets?

A: The product labeling specifies that the tablets should be stored at controlled room temperature, typically between 20 C and 25 C. To maintain the medicine's integrity, it should be protected from light and moisture, and it should be kept out of the sight and reach of children.

Q: Can I take this if I have kidney problems?

A: Regulatory documents include specific warnings and precautions regarding use in patients with pre-existing renal (kidney) impairment. Regulatory text includes information indicating that patients with renal impairment may require closer monitoring or potentially modified dosing, as outlined in the prescribing information.

Q: Can pregnant women use this medicine?

A: Official regulatory documents indicate that there are limited human data on use during pregnancy. The prescribing information specifies that the decision to use the medicine should weigh the potential benefits against the potential risks to the fetus, or that it may be contraindicated.

Storage and Disposal Conditions

Sildenafil Adair tablets must be stored according to official regulatory labeling to ensure product stability and safety.

Mandatory Storage Requirements

Condition	Requirement
Temperature	Store at a controlled room temperature, typically 20 C to 25 C.
Protection	Protect from excessive heat and moisture; do not freeze the tablets.
Container	Keep in the original container and ensure it is tightly closed.
Child Safety	Mandatory to keep out of the sight and reach of children.

Disposal Instructions

Dispose of any unused or expired Sildenafil Adair in accordance with local requirements. Official directives prohibit throwing the medication away through wastewater or household waste, to prevent environmental contamination.